Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 253,115,280
  • Shares Outstanding, K 2,529,635
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • EBIT $ 14,160 M
  • EBITDA $ 18,032 M
  • 60-Month Beta 0.39
  • Price/Sales 4.21
  • Price/Cash Flow 32.89
  • Price/Book 5.69

Options Overview Details

View History
  • Implied Volatility 25.73% ( +1.51%)
  • Historical Volatility 22.35%
  • IV Percentile 90%
  • IV Rank 69.85%
  • IV High 30.32% on 10/28/24
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 0.58
  • Today's Volume 21,690
  • Volume Avg (30-Day) 23,614
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 423,097
  • Open Int (30-Day) 412,606

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.80
  • Number of Estimates 6
  • High Estimate 1.90
  • Low Estimate 1.63
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +5,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
95.26 +3.23%
on 11/19/24
105.07 -6.40%
on 12/09/24
+1.78 (+1.84%)
since 11/18/24
3-Month
94.48 +4.09%
on 11/15/24
119.20 -17.50%
on 09/19/24
-20.30 (-17.11%)
since 09/18/24
52-Week
94.48 +4.09%
on 11/15/24
134.63 -26.96%
on 06/25/24
-7.70 (-7.26%)
since 12/18/23

Most Recent Stories

More News
Viking Therapeutics Stock Slides After Merck Strikes GLP-1 Deal With Chinese Biopharma, Retail Unperturbed

Viking’s own promising oral GLP-1 candidate, VK2735, is currently being studied for obesity and other metabolic conditions.

VKTX : 38.28 (-18.03%)
MRK : 98.34 (-1.72%)
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance

Merck MRK announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants...

AZN : 64.64 (-3.78%)
MRK : 98.34 (-1.72%)
PFE : 25.89 (-2.04%)
SNY : 47.01 (-3.94%)
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over

It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare...

ALK : 62.44 (-1.20%)
MRK : 98.34 (-1.72%)
JNJ : 144.75 (-1.13%)
NKE : 76.90 (-1.41%)
$DOWI : 42,326.87 (-2.58%)
AMGN : 258.78 (-2.70%)
BA : 172.62 (-0.24%)
Why Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy”

These two biotech companies look poised to deliver in the coming year.

PCVX : 85.75 (-4.57%)
$SPX : 5,872.16 (-2.95%)
MRK : 98.34 (-1.72%)
AIT : 244.46 (-3.87%)
PFE : 25.89 (-2.04%)
Top Analyst Reports for Alphabet, Oracle & Merck

Tuesday, December 10, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc....

GOOGL : 188.40 (-3.59%)
WFC : 68.76 (-2.90%)
MS : 121.04 (-5.25%)
MRK : 98.34 (-1.72%)
ORCL : 165.41 (-2.53%)
SCCO : 92.96 (-3.91%)
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation (BTD) to their antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd),...

AZN : 64.64 (-3.78%)
MRK : 98.34 (-1.72%)
PFE : 25.89 (-2.04%)
2 Healthcare Dividend Stocks to Hold for the Long Haul

Investors looking for stocks to hold on to for a while might want to consider dividend-paying companies. Besides offering a regular stream of passive income, dividend stocks have generally outperformed...

MRK : 98.34 (-1.72%)
MDT : 80.03 (-1.65%)
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday

Summit Therapeutics (NASDAQ: SMMT) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, investors...

SMMT : 16.98 (-8.56%)
MRK : 98.34 (-1.72%)
JEF : 75.76 (-4.33%)
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ

This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s...

AZN : 64.64 (-3.78%)
JNJ : 144.75 (-1.13%)
MRK : 98.34 (-1.72%)
LLY : 764.71 (-1.79%)
RHHBY : 34.9100 (-2.59%)
How Is Merck's Stock Performance Compared to Other Pharmaceuticals Stocks?

Merck has underperformed the pharmaceuticals industry over the past year, but analysts are highly optimistic about the stock’s prospects.

MRK : 98.34 (-1.72%)
PJP : 82.44 (-2.54%)
LLY : 764.71 (-1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 103.70
2nd Resistance Point 102.60
1st Resistance Point 100.47
Last Price 98.34
1st Support Level 97.24
2nd Support Level 96.14
3rd Support Level 94.01

See More

52-Week High 134.63
Fibonacci 61.8% 119.29
Fibonacci 50% 114.56
Fibonacci 38.2% 109.82
Last Price 98.34
52-Week Low 94.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar